SUN VALLEY, Calif., Aug. 22, 2007 (PRIME NEWSWIRE) -- Summus Works, Inc. (Pink Sheets:SMMW) announced that due to its recent acquisition of BioPharmetics assets and business operations, Paul D. Lisenby and Ben Friedman of BioPharmetics have been appointed to Summus' Board of Directors.
About Summus Works, Inc.
Summus Works recently closed an acquisition for the assets and business operations of BioPharmetics, Inc. Through this acquisition the company will have the ability to market and sell a myriad of healthcare, anti-aging, and cosmeceutical products to healthcare companies, retail and wholesale companies, as well targeting certain sectors of healthcare, biotechnology, and cosmetics.
For more information visit http://www.biopharmetics.com.
The Summus Works, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4093
This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic and business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.